The George Washington University Receives $134 Million Grant for Type 2 Diabetes Research
John Lachin, interim director of The George Washington University (GW) Biostatistics Center, received a five-year, $134 million grant for a clinical trial that will examine the most commonly used medications to treat Type 2 diabetes. The grant, awarded by the National Institute of Health’s National Institute of Diabetes and Digestive and Kidney Diseases, sets a record for the largest grant NVTC Board member GW has received.
The clinical trial, titled “Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study,” will study the long-term effectiveness of glucose-lowering medications used to treat individuals with Type 2 diabetes. GW’s Biostatistics Center will coordinate all research and operational activities at all sites for the study.
The initial steps of the project will begin Oct. 1. The $134 million grant supports the first five years of the project, with the opportunity for renewal for an additional three years. The project duration is scheduled to be eight years. For more information, click here.